$783 Million is the total value of Rhenman & Partners Asset Management AB's 94 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 26.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HZNP | Buy | Horizon Pharma Plc | $38,127,000 | +32.6% | 3,006,862 | +24.1% | 4.87% | +17.9% |
| VRTX | Buy | Vertex Pharmaceuticals Inc | $27,367,000 | +123.5% | 180,000 | +89.4% | 3.49% | +98.7% |
| ABMD | Buy | Abiomed Inc | $23,644,000 | +55.4% | 140,238 | +32.1% | 3.02% | +38.2% |
| ALXN | Buy | Alexion Pharmaceuticals Inc | $23,148,000 | +23.5% | 165,000 | +7.1% | 2.96% | +9.9% |
| CELG | Buy | Celgene Corp | $22,165,000 | +20.2% | 152,000 | +7.0% | 2.83% | +6.9% |
| GKOS | Buy | Glaukos Corp | $21,377,000 | +49.2% | 647,796 | +87.5% | 2.73% | +32.7% |
| NKTR | Buy | Nektar Therapeutics | $20,789,000 | +33.8% | 866,194 | +9.0% | 2.65% | +18.9% |
| AGN | Buy | Allergan Plc | $20,495,000 | +62.1% | 100,000 | +92.3% | 2.62% | +44.1% |
| ADMS | Buy | Adamas Pharmaceuticals Inc | $19,371,000 | +200.8% | 915,000 | +148.5% | 2.47% | +167.4% |
| ITCI | Buy | Intra-Cellular Therapies Inc | $18,619,000 | +79.9% | 1,179,900 | +41.6% | 2.38% | +60.0% |
| MDT | Buy | Medtronic Plc | $16,652,000 | -1.8% | 214,115 | +12.0% | 2.13% | -12.7% |
| PTLA | Buy | Portola Pharmaceuticals Inc | $16,069,000 | +158.2% | 297,400 | +168.4% | 2.05% | +129.4% |
| ESRX | Buy | Express Scripts Hg Co | $15,513,000 | +55.8% | 245,000 | +57.1% | 1.98% | +38.5% |
| ARNA | New | Arena Pharmaceuticals Inc Reg | $14,522,000 | – | 569,491 | +100.0% | 1.85% | – |
| ABBV | Buy | AbbVie Inc | $12,440,000 | +27.1% | 140,000 | +3.7% | 1.59% | +12.9% |
| CNC | Buy | Centene Corp | $10,645,000 | +33.3% | 110,000 | +10.0% | 1.36% | +18.5% |
| ANTM | Buy | Anthem Inc | $10,443,000 | +109.7% | 55,000 | +107.8% | 1.33% | +86.4% |
| CI | Buy | Cigna Corp | $10,282,000 | +36.5% | 55,000 | +22.2% | 1.31% | +21.3% |
| BMY | Buy | Bristol Myers Squibb Co | $10,230,000 | +61.6% | 160,502 | +41.3% | 1.31% | +43.7% |
| HUM | Buy | Humana Inc | $9,989,000 | +18.6% | 41,000 | +17.1% | 1.28% | +5.5% |
| AET | Buy | Aetna Inc | $9,859,000 | +75.5% | 62,000 | +67.6% | 1.26% | +56.0% |
| REGN | Buy | Regeneron Pharmaceuticals Inc | $9,837,000 | +32.6% | 22,000 | +45.7% | 1.26% | +17.9% |
| CVS | Buy | CVS Health Corp | $9,758,000 | +42.7% | 120,000 | +41.2% | 1.25% | +26.9% |
| EW | Buy | Edwards Lifesciences Corp | $8,745,000 | +124.1% | 80,000 | +142.4% | 1.12% | +99.3% |
| ABT | Buy | Abbott Laboratories | $8,271,000 | +79.1% | 155,000 | +63.2% | 1.06% | +59.3% |
| BSX | New | Boston Scientific Corp | $8,181,000 | – | 280,468 | +100.0% | 1.04% | – |
| ARRY | Buy | Array BioPharma Inc | $7,995,000 | +124.8% | 650,000 | +52.9% | 1.02% | +99.8% |
| ALKS | Buy | Alkermes Plc | $7,372,000 | -6.1% | 145,000 | +7.1% | 0.94% | -16.5% |
| LOXO | New | Loxo Oncology Inc | $6,909,000 | – | 75,000 | +100.0% | 0.88% | – |
| RVNC | Buy | Revance Therapeutics Inc | $6,788,000 | +16.9% | 246,400 | +12.0% | 0.87% | +4.0% |
| ABC | Buy | AmerisourceBergen Corp | $6,620,000 | +55.6% | 80,000 | +77.8% | 0.84% | +38.3% |
| MYOK | New | MyoKardia Inc Reg | $6,465,000 | – | 150,872 | +100.0% | 0.82% | – |
| RIGL | Buy | Rigel Pharmaceuticals Inc | $5,969,000 | +58.9% | 2,350,000 | +70.8% | 0.76% | +41.4% |
| AERI | Buy | Aerie Pharmaceuticals Inc | $5,877,000 | +49.1% | 120,932 | +61.2% | 0.75% | +32.5% |
| DXCM | Buy | Dexcom Inc | $5,871,000 | -23.1% | 120,000 | +15.0% | 0.75% | -31.7% |
| IOVA | Buy | Iovance Biotherapeutics Inc Reg | $5,512,000 | +15.4% | 711,163 | +9.4% | 0.70% | +2.6% |
| RARE | Buy | Ultragenyx Pharmaceutical Inc | $5,326,000 | +141.1% | 100,000 | +181.1% | 0.68% | +114.5% |
| JUNO | New | Juno Therapeutics Inc | $4,486,000 | – | 100,000 | +100.0% | 0.57% | – |
| MGNX | Buy | Macrogenics Inc | $4,101,000 | +33.8% | 221,914 | +26.8% | 0.52% | +19.1% |
| RAD | Buy | Rite Aid Corp | $3,996,000 | +286.8% | 2,039,000 | +482.6% | 0.51% | +244.6% |
| NVO | New | Novo Nordisk AS ADR Repr 1 Share Badr | $3,852,000 | – | 80,000 | +100.0% | 0.49% | – |
| ACHN | Buy | Achillion Pharmaceuticals Inc | $3,817,000 | +400.9% | 850,000 | +412.0% | 0.49% | +346.8% |
| RDUS | Buy | Radius Health Inc | $3,470,000 | +2.3% | 90,000 | +20.0% | 0.44% | -9.0% |
| DERM | New | Dermira Inc Reg | $2,700,000 | – | 100,000 | +100.0% | 0.34% | – |
| CHRS | Buy | Coherus BioSciences Inc | $2,403,000 | -0.8% | 180,000 | +6.6% | 0.31% | -11.8% |
| ICPT | Buy | Intercept Pharmaceuticals Inc | $2,322,000 | +537.9% | 40,000 | +1229.8% | 0.30% | +469.2% |
| BIVV | Buy | Bioverativ Inc Reg S | $1,997,000 | +7.1% | 35,000 | +12.9% | 0.26% | -4.9% |
| RARX | New | Ra Pharmaceuticals Inc Reg | $1,748,000 | – | 119,697 | +100.0% | 0.22% | – |
| STAA | Buy | Staar Surgical Co | $1,121,000 | +48.5% | 90,000 | +28.7% | 0.14% | +32.4% |
| NLNK | New | NewLink Genetics Corp | $1,018,000 | – | 100,000 | +100.0% | 0.13% | – |
| AGIO | New | Agios Pharmaceuticals Inc | $1,001,000 | – | 15,000 | +100.0% | 0.13% | – |
| JPM | Buy | JPMorgan Chase & Co | $539,000 | +21.9% | 5,641 | +16.6% | 0.07% | +9.5% |
| HAL | Buy | Halliburton Co (Hg Co) | $513,000 | +55.5% | 11,144 | +44.4% | 0.06% | +38.3% |
| WFC | Buy | Wells Fargo & Co | $477,000 | +17.8% | 8,653 | +18.5% | 0.06% | +5.2% |
| XOM | Buy | Exxon Mobil Corp | $467,000 | +20.1% | 5,696 | +18.1% | 0.06% | +7.1% |
| New | Janus Henderson Group Plc Regnote | $472,000 | – | 13,556 | +100.0% | 0.06% | – | |
| SYMC | New | Symantec Corp | $307,000 | – | 9,359 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-10-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.